Literature DB >> 23430881

Cerebral edema in maple syrup urine disease despite newborn screening diagnosis and early initiation of treatment.

Kenneth A Myers1, Melanie Reeves, Xing-Chang Wei, Aneal Khan.   

Abstract

A 7-day-old girl had an elevated leucine level on newborn screen drawn at 2 days of age and was suspected of having maple syrup urine disease (MSUD). When reported, the patient was immediately admitted to hospital, and started on a modified diet involving high calories with reduced branched chain amino acid (BCAA) formula. Clinical exam was normal at initial assessment. Despite rapid initiation of treatment, the baby became lethargic and somnolent over the next day. Diet was stopped and infusions of 12.5% dextrose and 20% intravenous lipids at 2 g/kg per day were immediately started. Lethargy improved within 3 h of intravenous therapy initiation. Brain magnetic resonance imaging demonstrated diffuse cerebral edema, and symmetric restricted diffusion in bilateral cerebellar white matter, dorsal brainstem, thalami, globi pallidi, posterior limbs of internal capsules, and corona radiata. Plasma leucine was 1.98 mmol/L on admission (normal 0.05-0.17 mmol/L), decreasing to 1.34 mmol/L with diet, however clinical deterioration occurred despite improving leucine levels.Cerebral edema in MSUD is thought secondary to a combination of increased cerebral BCAA levels, and depleted levels of other essential amino acids, as well as neurotransmitters. Our case illustrates that newborns can develop encephalopathy with cerebral edema despite treatment with special formula initiated while asymptomatic. These findings suggest decompensation may begin early on, so that early introduction of high dextrose infusion and intravenous lipids, in combination with reduced BCAA formula, should be initiated for any patient with a positive newborn screen for MSUD.

Entities:  

Year:  2011        PMID: 23430881      PMCID: PMC3509865          DOI: 10.1007/8904_2011_69

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  10 in total

1.  Maple syrup urine disease: diffusion MRI, and proton MR spectroscopy findings.

Authors:  R Nuri Sener
Journal:  Comput Med Imaging Graph       Date:  2007-01-04       Impact factor: 4.790

2.  Contribution of the diffusion-weighted MRI in the diagnosis and follow-up of encephalopathy caused by maple syrup urine disease in a full-term newborn.

Authors:  José Roberto Lopes Ferraz-Filho; Valdeci Hélio Floriano; Marcelo Bianco Quirici; Regina Pires de Albuquerque; Antônio Soares Souza
Journal:  Arq Neuropsiquiatr       Date:  2009-09       Impact factor: 1.420

3.  Age dependence of diffusion-weighted magnetic resonance imaging findings in maple syrup urine disease encephalopathy.

Authors:  Mio Sakai; Yusuke Inoue; Hiroshi Oba; Akira Ishiguro; Kyoko Sekiguchi; Yoshihiko Tsukune; Masanori Mitomo; Hironobu Nakamura
Journal:  J Comput Assist Tomogr       Date:  2005 Jul-Aug       Impact factor: 1.826

4.  Effect of the branched-chain alpha-keto acids on pyruvate metabolism by homogenates of human brain.

Authors:  M S Patel; V H Auerbach; W D Grover; D O Wilbur
Journal:  J Neurochem       Date:  1973-06       Impact factor: 5.372

5.  Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants.

Authors:  J Brismar; A Aqeel; G Brismar; R Coates; G Gascon; P Ozand
Journal:  AJNR Am J Neuroradiol       Date:  1990 Nov-Dec       Impact factor: 3.825

6.  MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation.

Authors:  Wajanat Jan; Robert A Zimmerman; Zhiyue J Wang; Gerard T Berry; Paige B Kaplan; Edward M Kaye
Journal:  Neuroradiology       Date:  2003-05-08       Impact factor: 2.804

7.  Diffusion-weighted MRI of maple syrup urine disease encephalopathy.

Authors:  F Cavalleri; A Berardi; A B Burlina; F Ferrari; L Mavilla
Journal:  Neuroradiology       Date:  2002-04-24       Impact factor: 2.804

8.  Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Angela M Sgaravatti; Rafael B Rosa; Patrícia F Schuck; César A J Ribeiro; Clóvis M D Wannmacher; Angela T S Wyse; Carlos S Dutra-Filho; Moacir Wajner
Journal:  Biochim Biophys Acta       Date:  2003-11-20

9.  Classical maple syrup urine disease and brain development: principles of management and formula design.

Authors:  Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton
Journal:  Mol Genet Metab       Date:  2010-01-12       Impact factor: 4.797

10.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.

Authors:  William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

  10 in total
  3 in total

1.  MRI and clinical features of maple syrup urine disease: preliminary results in 10 cases.

Authors:  Ailan Cheng; Lianshu Han; Yun Feng; Huimin Li; Rong Yao; Dengbin Wang; Biao Jin
Journal:  Diagn Interv Radiol       Date:  2017 Sep-Oct       Impact factor: 2.630

2.  Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report.

Authors:  Jessie Aw-Zoretic; Nitin R Wadhwani; Rishi R Lulla; Lulla R Rishi; Maura E Ryan
Journal:  Childs Nerv Syst       Date:  2015-06-18       Impact factor: 1.475

3.  A Novel Whole Gene Deletion of BCKDHB by Alu-Mediated Non-allelic Recombination in a Chinese Patient With Maple Syrup Urine Disease.

Authors:  Gang Liu; Dingyuan Ma; Ping Hu; Wen Wang; Chunyu Luo; Yan Wang; Yun Sun; Jingjing Zhang; Tao Jiang; Zhengfeng Xu
Journal:  Front Genet       Date:  2018-04-24       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.